Gitrabin 2000 mg prašak za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

gitrabin 2000 mg prašak za otopinu za infuziju

teva b.v., swensweg 5, haarlem, nizozemska - gemcitabinklorid - prašak za otopinu za infuziju - 2000 mg - urbroj: svaka bočica sadrži 2000 mg gemcitabina (u obliku gemcitabinklorida)

Protravis 40 mikrograma/ml kapi za oko, otopina Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

protravis 40 mikrograma/ml kapi za oko, otopina

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - травопрост - kapi za oko, otopina - 40 mikrograma/ml - urbroj: svaki ml otopine sadrži 40 mikrograma travoprosta

Bravis 10 mg/ml kapi za oko, suspenzija Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bravis 10 mg/ml kapi za oko, suspenzija

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - brinzolamid - kapi za oko, suspenzija - 10 mg/ml - urbroj: jedan ml suspenzije sadrži 10 mg brinzolamida

Byooviz Europska Unija - hrvatski - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ximluci Europska Unija - hrvatski - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ranivisio Europska Unija - hrvatski - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).